The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11,996.00
Bid: 11,996.00
Ask: 11,998.00
Change: -32.00 (-0.27%)
Spread: 2.00 (0.017%)
Open: 12,052.00
High: 12,094.00
Low: 11,956.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Pfizer Inc

22 May 2014 10:50

RNS Number : 8151H
Morgan Stanley Capital Services LLC
22 May 2014
 



 

 FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Morgan Stanley Capital Services LLC

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PFIZER INC

(c) Name of the party to the offer with which exempt principal trader is connected:

 

ASTRAZENECA PLC

(d) Date dealing undertaken:

21 MAY 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

 Class of relevant security

 Purchases/sales

 Total number of securities

 Highest price per unit paid/received

 Lowest price per unit paid/received

 COMMON STOCK

 PURCHASES

 239,238

 29.6203 USD

 29.2700 USD

 COMMON STOCK

 SALES

 339,974

 29.6203 USD

 29.2400 USD

 

 

(b) Derivatives transactions (other than options)

 

 Class of relevant security

 Product description

e.g. CFD

 Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 Number of reference securities

 Price per unit

 COMMON STOCK

 CFD

 LONG

 1,300

 29.3900 USD

 COMMON STOCK

 CFD

 LONG

 21,480

 29.4411 USD

 COMMON STOCK

 CFD

 LONG

 2,200

 29.4420 USD

 COMMON STOCK

 CFD

 LONG

 13,400

 29.4960 USD

 COMMON STOCK

 CFD

 LONG

 38,900

 29.5316 USD

 COMMON STOCK

 CFD

 LONG

 5

 29.5360 USD

 COMMON STOCK

 CFD

 LONG

 13,681

 29.5407 USD

 COMMON STOCK

 CFD

 LONG

 60,085

 29.5415 USD

 COMMON STOCK

 CFD

 LONG

 32,134

 29.5420 USD

 COMMON STOCK

 CFD

 LONG

 123

 29.5428 USD

 COMMON STOCK

 CFD

 LONG

 2

 29.5428 USD

 COMMON STOCK

 CFD

 LONG

 2

 29.5431 USD

 COMMON STOCK

 CFD

 LONG

 111

 29.5431 USD

 COMMON STOCK

 CFD

 LONG

 1

 29.5432 USD

 COMMON STOCK

 CFD

 LONG

 110

 29.5432 USD

 COMMON STOCK

 CFD

 LONG

 2,900

 29.5436 USD

 COMMON STOCK

 CFD

 LONG

 2

 29.5463 USD

 COMMON STOCK

 CFD

 LONG

 30

 29.5463 USD

 COMMON STOCK

 CFD

 LONG

 100

 29.5500 USD

 COMMON STOCK

 CFD

 LONG

 4,200

 29.5500 USD

 COMMON STOCK

 CFD

 LONG

 5,500

 29.5554 USD

 COMMON STOCK

 CFD

 LONG

 29,692

 29.5630 USD

 COMMON STOCK

 CFD

 LONG

 21,700

 29.5677 USD

 COMMON STOCK

 CFD

 LONG

 5

 29.5680 USD

 COMMON STOCK

 CFD

 LONG

 79,605

 29.5730 USD

 COMMON STOCK

 CFD

 LONG

 1,992

 29.5753 USD

 COMMON STOCK

 CFD

 LONG

 700

 29.5785 USD

 COMMON STOCK

 CFD

 LONG

 1,818

 29.5788 USD

 COMMON STOCK

 CFD

 LONG

 279

 29.5788 USD

 COMMON STOCK

 CFD

 SHORT

 1

 29.4800 USD

 COMMON STOCK

 CFD

 SHORT

 400

 29.5300 USD

 COMMON STOCK

 CFD

 SHORT

 9,600

 29.5458 USD

 COMMON STOCK

 CFD

 SHORT

 300

 29.5500 USD

 COMMON STOCK

 CFD

 SHORT

 2,200

 29.5600 USD

 COMMON STOCK

 CFD

 SHORT

 500

 29.5625 USD

 COMMON STOCK

 CFD

 SHORT

 125,000

 29.5700 USD

 COMMON STOCK

 CFD

 SHORT

 1,000

 29.5700 USD

 COMMON STOCK

 CFD

 SHORT

 45,500

 29.5747 USD

 COMMON STOCK

 CFD

 SHORT

 18,100

 29.5842 USD

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

 Class of relevant security

 Product description e.g. call option

 Writing, purchasing, selling, varying etc.

 Number of securities to which option relates

 Exercise price per unit

 Type e.g. American, European etc.

 Expiry date

 Option money paid/ received per unit

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 

(ii) Exercising

 

 Class of relevant security

 Product description e.g. call option

 Number of securities

 Exercise price per unit

 N/A

 N/A

 N/A

 N/A

 

(d) Other dealings (including subscribing for new securities)

 

 Class of relevant security

 Nature of dealing e.g. subscription, conversion

 Details

 Price per unit (if applicable)

 N/A

 N/A

 N/A

 N/A

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

Date of disclosure:

22 MAY 2014

Contact name:

Darren Wickert

Telephone number:

+44 (0)20 7425 6578

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERGCGDURSDBGSD
Date   Source Headline
25th Sep 20181:15 pmRNSOverall survival data for Imfinzi: Stage III NSCLC
24th Sep 20184:10 pmRNSEMA approves AZ's Imfinzi for Stage III NSCLC
24th Sep 20187:00 amRNSFarxiga gets positive result in DECLARE-TIMI 58
14th Sep 20187:00 amRNSFDA approves AZ's Lumoxiti in hairy cell leukaemia
7th Sep 20187:00 amRNSTezepelumab FDA Breakthrough Therapy Designation
6th Sep 20187:00 amRNSDirectorate Change
3rd Sep 20183:00 pmRNSTotal Voting Rights
31st Aug 20187:00 amRNSAstraZeneca Update on Anifrolumab in SLE
30th Aug 20187:00 amRNSEC approves Bydureon BCise device for T2 diabetes
23rd Aug 20187:00 amRNSAstraZeneca PIIIb trial update for Bevespi in COPD
21st Aug 20187:00 amRNSAZ's Tagrisso approved in Japan for 1st-line NSCLC
15th Aug 20187:00 amRNSAstraZeneca prices a $3bn bond issue
3rd Aug 20187:00 amRNSEMA grants OD for selumetinib in NF1
1st Aug 20183:00 pmRNSTotal Voting Rights
27th Jul 20182:00 pmRNSCHMP recommends Imfinzi for Stage III nsclc
26th Jul 20187:00 amRNSAZN: H1 2018 Results
24th Jul 20187:00 amRNSAtacand to be divested to Cheplapharm in Europe
18th Jul 20184:11 pmRNSHolding(s) in Company
18th Jul 201812:00 pmRNSHolding(s) in Company
2nd Jul 20183:00 pmRNSTotal Voting Rights
2nd Jul 20187:00 amRNSImfinzi approved in Japan for Stage III nsclc
2nd Jul 20187:00 amRNSLynparza approved in Japan for BRCAm breast cancer
29th Jun 20183:00 pmRNSBydureon receives positive CHMP opinion for BCise
28th Jun 20181:30 pmRNSAZ and Luye Pharma complete agreement for Seroquel
27th Jun 20187:00 amRNSLynparza: significant PFS 1st-line ovarian cancer
26th Jun 20187:00 amRNSBoard Committee Changes
22nd Jun 20187:00 amRNSPublication of a Prospectus
12th Jun 20187:00 amRNSUpdate: lanabecestat Phase III Alzheimer's trials
8th Jun 20185:30 pmRNSEU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
8th Jun 20187:00 amRNSDirector Declaration
1st Jun 20183:00 pmRNSBlock listing Interim Review
1st Jun 20183:00 pmRNSTotal Voting Rights
1st Jun 201811:00 amRNSDirector Declaration
30th May 20187:00 amRNSUpdate on TERRANOVA PIII trial for Fasenra in COPD
25th May 20187:00 amRNSAZ's Imfinzi: significant OS in Stage III nsclc
21st May 20187:00 amRNSAZ regulatory submission in Japan for Forxiga
21st May 20187:00 amRNSUS FDA approves Lokelma for adult hyperkalaemia
18th May 20185:30 pmRNSResult of AGM
18th May 20187:00 amRNSAZN: Q1 2018 Results
11th May 20187:00 amRNSAstraZeneca update on Fasenra PIII trial in COPD
8th May 201811:00 amRNSEMA approves Lynparza: maintenance ovarian cancer
8th May 20187:00 amRNSAZ and Luye Pharma enter agreement for Seroquel
4th May 201812:00 pmRNSDirector Declaration
1st May 20183:00 pmRNSTotal Voting Rights
27th Apr 201812:30 pmRNSAZ: positive CHMP for Tagrisso first-line nsclc
24th Apr 20187:00 amRNSAstraZeneca:high level results of the ARCTIC trial
24th Apr 20187:00 amRNSIssue of Equity - AstraZeneca
19th Apr 20187:00 amRNSFDA approves Tagrisso for 1st-line use in NSCLC
13th Apr 201811:00 amRNSNotice of AGM
5th Apr 20187:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.